Evaluation of therapies in oncology by positron emission tomography: towards therapeutical personnalization

被引：4

作者：

Bonardel, G. ^{[1
]}

Vedrine, L. ^{[2
]}

Aupee, O. ^{[1
]}

Gontier, E. ^{[1
]}

Le Garlantezec, P. ^{[1
]}

Soret, M. ^{[1
]}

Foehrenbach, H. ^{[1
]}

机构：

[1] HIA Val Grace, Nucl Med Serv, F-75005 Paris, France

[2] HIA Val Grace, Serv Oncol & Radiotherapie, F-75005 Paris, France

来源：

BULLETIN DU CANCER | 2009年 / 96卷 / 02期

关键词：

FDG-PET; therapeutic evaluation; treatment personnalization; oncology; BREAST-CANCER; F-18-FDG PET; FDG-PET; FLUORINATED TRACERS; GENE-EXPRESSION; IMAGING CANCER; LYMPHOMA; PROLIFERATION; LUNG; VIABILITY;

D O I：

10.1684/bdc.2008.0816

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recently introduced into clinical practice, positron emission tomography ( PET) with 18F-fluorodeoxyglucose (FDG) has proven its utility for diagnosis and staging of malignant diseases on account of its ability for tissue identification. Its utilization is now moving toward the evaluation of anti-tumoral effects of anticancer therapy, because of the correlation between the uptake of a metabolic tracer and malignant cells viability. Metabolic effects of chemotherapy are first observed in cells and this is the explanation for the precocity of scintigraphic vizualisation of therapeutic activity. However, monitoring response with FDG-PET requires rigorous method and needs to take into account the limitations of SUV. Moreover, in order to go beyond the limitations of FDG, new tracers are developed and their main indication could be precisely the monitoring of therapy response. The properties of positron emitters allow us to foresee the labelling of the therapeutic molecules themselves in order to try them in vivo before their utilization for a given patient. These prospects are the ground for real treatment personnalization in oncology. They open up a wide field of clinical research but the means for image acquisition and radioactive tracers production will be mandatory for anyone who wants to contribute to this work. Due to the current performances of the imaging systems, the critical point will be availability of equipment allowing the designing and synthesis of the radiopharmaceuticals of the future.

引用

页码：213 / 226

页数：14

共 37 条

[1]

Al-Nahhas A, 2008, IN VIVO, V22, P109

[2] Imaging of cell proliferation: Status and prospects [J].

Bading, James R. ;

Shieds, Anthony F. .

JOURNAL OF NUCLEAR MEDICINE, 2008, 49 :64S-80S

[3] New tracers developed in positron emission tomography: A possible second breath in targeting tumour hypoxia? [J].

Baillet, G. ;

Groheux, D. ;

Barre, E. ;

Toubert, M. -E. ;

Dechaud, C. ;

Teyton, P. ;

de Hemricourt, E. Le Beau ;

Moretti, J. -L. .

MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2008, 32 (12) :607-613

[4] Patterns of αvβ3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET [J].

Beer, Ambros J. ;

Niemeyer, Markus ;

Carlsen, Janette ;

Sarbia, Mario ;

Naehrig, Joerg ;

Watzlowik, Petra ;

Wester, Hans-Juergen ;

Harbeck, Nadia ;

Schwaiger, Markus .

JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (02) :255-259

[5]

Buvat I., 2007, Medecine Nucleaire, V31, P165, DOI 10.1016/j.mednuc.2007.03.003

[6]

Cachin F, 2006, B CANCER, V93, P1191

[7] Fluorinated tracers for imaging cancer with positron emission tomography [J].

Couturier, O ;

Luxen, A ;

Chatal, JF ;

Vuillez, JP ;

Rigo, P ;

Hustinx, R .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (08) :1182-1206

[8]

Couturier O, 2004, B CANCER, V91, P695

[9]

Engles JM, 2006, J NUCL MED, V47, P603

[10] Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans [J].

Freedman, NMT ;

Sundaram, SK ;

Kurdziel, K ;

Carrasquillo, JA ;

Whatley, M ;

Carson, JM ;

Sellers, D ;

Libutti, SK ;

Yang, JC ;

Bacharach, SL .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (01) :46-53

← 1 2 3 4 →